ATRT-23. SMARCB1-DEPENDENCIES IN ATYPICAL TERATOID/RHABDOID TUMOURS: A STRATEGY FOR PRE-CLINICAL THERAPEUTIC TARGET IDENTIFICATION IN THE ABSENCE OF ACTIONABLE MUTATIONS

ATRTs have low mutation rates and few classically-actionable variants to direct molecularly targeted therapies; loss of SMARCB1 is the sole recurrent mutational event in >90% of ATRTs. We have designed and implemented a genome-scale strategy for target identification and prioritization in tumors...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Finetti, Martina Anna, Selby, Matthew p, Pons, Alicia del-Carpio, Batting, Sarah, Wood, James A, Barker, James M, Smith, Amanda, Crosier, Stephen, Bashton, Matthew, Pickles, Jessica C, Fairchild, Amy R, Avery, Aimee, O’Hare, Patricia, Pizer, Barry, Brennan, Bernadette, Lowis, Stephen, Hargrave, Darren, Jacques, Thomas S, Bailey, Simon, Clifford, Steven C, Williamson, Daniel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012497/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.021
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia